OPKO Health, Inc. (OPK) Income Statement
OPK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOPK revenue and net income
Where OPK's revenue goes
2025Each bar shows an amount and its share of revenue. OPK kept −37.2% of revenue as net income.
OPK profit margins
OPK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −14.9% | −15.5% | −15.8% | +2.1% |
| Gross profit | −58.8% | −23.7% | −25.0% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OPK quarterly EPS vs estimates
OPKO Health beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.07).
OPK income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.9M | $713.1M | $863.5M | $1.00B | $1.77B | $1.44B | $901.9M | $990.3M | $966.0M | $1.22B |
| Cost of revenue | $478.8M | $402.1M | $545.4M | $716.0M | $1.19B | $894.4M | $572.5M | $604.6M | $620.1M | $611.5M |
| Gross profit | $128.1M | $311.0M | $318.1M | $288.2M | $581.5M | $541.0M | $329.5M | $385.7M | $345.9M | $610.2M |
| Research & development | $124.0M | $105.2M | $89.6M | $73.9M | $76.8M | $75.3M | $117.9M | $135.7M | $126.4M | $113.9M |
| Sales, general & admin | $223.0M | $304.2M | $301.7M | $372.7M | $468.9M | $355.6M | $343.3M | $358.3M | $521.0M | $490.9M |
| Total operating expenses | $347.0M | $463.1M | $475.1M | $514.5M | $562.8M | $483.3M | $603.5M | $551.9M | $625.7M | $602.6M |
| Operating income | −$219.0M | −$152.1M | −$157.0M | −$226.3M | $18.8M | $57.7M | −$274.1M | −$171.2M | −$276.4M | −$73.3M |
| Interest income | $14.8M | $8.4M | $4.2M | $2.0M | $28,000 | $152,000 | $1.7M | $1.2M | $610,000 | $478,000 |
| Interest expense | $108.5M | $47.5M | $13.5M | $12.1M | $18.9M | $21.9M | $21.5M | $11.9M | $6.6M | $7.4M |
| Income before taxes | −$241.4M | −$10.4M | −$184.4M | −$391.9M | −$14.7M | $48.2M | −$305.0M | −$177.3M | −$271.9M | −$73.5M |
| Income taxes | −$15.7M | $42.8M | $4.4M | −$63.5M | $15.5M | $17.6M | $7.1M | −$38.7M | $18.9M | −$56.1M |
| Net income | −$225.7M | −$53.2M | −$188.9M | −$328.4M | −$30.1M | $30.6M | −$314.9M | −$153.0M | −$305.2M | −$48.4M |
| EBITDA | −$41.3M | $135.3M | −$65.5M | −$270.8M | $83.6M | $156.0M | −$189.6M | −$68.0M | −$163.2M | $7.2M |
| EPS (diluted) | −$0.18 | −$0.09 | −$0.25 | −$0.44 | −$0.05 | $0.05 | −$0.53 | −$0.25 | −$0.49 | −$0.09 |
| Gross margin | 21.1% | 43.6% | 36.8% | 28.7% | 32.8% | 37.7% | 36.5% | 38.9% | 35.8% | 49.9% |
| Operating margin | −36.1% | −21.3% | −18.2% | −22.5% | 1.1% | 4.0% | −30.4% | −17.3% | −28.6% | −6.0% |
| Net margin | −37.2% | −7.5% | −21.9% | −32.7% | −1.7% | 2.1% | −34.9% | −15.5% | −31.6% | −4.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $163.6M | $124.2M | $148.4M | $151.7M | $156.8M | $150.0M | $183.6M | $173.6M | $182.2M | $173.7M | $181.9M | $178.6M |
| Cost of revenue | $83.6M | $97.4M | $103.5M | $121.3M | $126.8M | $127.2M | $99.0M | $133.5M | $130.5M | $131.6M | $137.2M | $130.9M |
| Gross profit | $80.0M | $26.8M | $45.0M | $30.4M | $30.0M | $22.8M | $84.7M | $40.1M | $51.7M | $42.1M | $44.7M | $47.7M |
| Research & development | $33.2M | $29.2M | $32.8M | $30.1M | $30.3M | $30.8M | $30.4M | $28.8M | $24.1M | $21.9M | $19.4M | $19.4M |
| Sales, general & admin | $52.9M | $48.6M | $50.5M | $53.8M | $59.6M | $59.1M | $67.0M | $98.2M | $68.8M | $70.2M | $72.9M | $72.3M |
| Total operating expenses | $87.0M | $77.8M | $83.3M | $83.9M | $89.9M | $89.9M | $117.8M | $25.9M | $113.3M | $113.5M | $113.8M | $112.1M |
| Operating income | −$7.0M | −$51.0M | −$38.3M | −$53.5M | −$60.0M | −$67.2M | −$33.1M | $14.2M | −$61.7M | −$71.5M | −$69.0M | −$64.4M |
| Interest income | $3.2M | $3.0M | $3.8M | $3.0M | $3.3M | $4.7M | $4.3M | $2.9M | $391,000 | $813,000 | $906,000 | $970,000 |
| Interest expense | $11.4M | $10.9M | $11.3M | $11.4M | $70.3M | $15.5M | $14.2M | $17.4M | $8.2M | $7.7M | $3.5M | $3.4M |
| Income before taxes | −$13.4M | −$61.0M | −$46.9M | $41.4M | −$162.5M | −$73.4M | $35.0M | $48.4M | −$10.6M | −$83.2M | −$72.5M | −$78.4M |
| Income taxes | −$5.0M | −$6.1M | −$15.7M | $19.8M | −$14.1M | −$5.8M | $20.9M | $23.5M | −$280,000 | −$1.4M | −$6.0M | $6.1M |
| Net income | −$8.4M | −$54.8M | −$31.3M | $21.6M | −$148.4M | −$67.6M | $14.0M | $24.9M | −$10.3M | −$81.8M | −$66.5M | −$84.5M |
| EBITDA | $15.4M | −$27.8M | −$13.2M | $75.5M | −$69.2M | −$34.4M | $73.2M | $89.9M | $21.8M | −$49.7M | −$43.1M | −$48.7M |
| EPS (diluted) | −$0.01 | −$0.07 | −$0.04 | $0.03 | −$0.08 | −$0.09 | $0.01 | $0.03 | −$0.01 | −$0.12 | −$0.09 | −$0.11 |
| Gross margin | 48.9% | 21.6% | 30.3% | 20.0% | 19.1% | 15.2% | 46.1% | 23.1% | 28.4% | 24.2% | 24.6% | 26.7% |
| Operating margin | −4.3% | −41.1% | −25.8% | −35.3% | −38.3% | −44.8% | −18.0% | 8.2% | −33.9% | −41.2% | −38.0% | −36.1% |
| Net margin | −5.1% | −44.2% | −21.1% | 14.3% | −94.7% | −45.1% | 7.6% | 14.3% | −5.7% | −47.1% | −36.5% | −47.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OPK's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OPK financial results
In fiscal year 2025 (ended December 31, 2025), OPKO Health reported revenue of $606.9 million, down 14.9% from the year before. It had a net loss of $225.7 million, a net profit margin of −37.2%. Diluted earnings per share came to −$0.18. Over five years revenue grew at an average rate of −15.8% a year.
See the OPK stock overview for the latest quote and news, or the OPK chart for price history and technical indicators.
OPK income statement FAQ
What is OPKO Health's annual revenue?
OPKO Health reported total revenue of $606.9 million for fiscal year 2025, which ended on December 31, 2025. That was down 14.9% from $713.1 million the previous year.
Is OPKO Health profitable?
No. OPKO Health reported a net loss of $225.7 million in fiscal 2025, a net profit margin of −37.2%; its operating margin was −36.1%.
What is OPKO Health's gross margin?
OPKO Health's gross margin was 21.1% in fiscal 2025: for every $100 of revenue, OPKO Health kept $21 after the direct cost of its products and services.
How much does OPKO Health spend on research and development?
OPKO Health spent $124.0 million on research and development in fiscal 2025, 20.4% of revenue.
How fast is OPKO Health growing?
Revenue grew −15.8% a year on average over the last five fiscal years, from $1.4 billion to $606.9 million.
What are OPKO Health's earnings per share?
OPKO Health earned $-0.18 per diluted share in fiscal 2025, compared with $-0.09 a year earlier.
When will OPKO Health report its next earnings?
OPKO Health is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does OPKO Health's fiscal year end?
OPKO Health's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.